KR100850474B1 - Pharmaceutical composition for cancer chemoprevention comprising the extracts of cutleria cylindrica - Google Patents

Abstract

A pharmaceutical composition comprising the extract of Cutleria cylindrical is provided to induce activity of quinone reductase, lead no an activity of phase 1 detoxification enzyme system but an activity of phase 2 detoxification enzyme system, inhibit cytotoxicity, and suppress increase carcinogenic and procarcinogenic materials and promote their release. A pharmaceutical composition for cancer chemoprevention comprises 0.001-99.9 wt.% of the extract of Cutleria cylindrical which is prepared by washing Cutleria cylindrical collected with water to remove foreign substances and salt, drying the Cutleria cylindrical, extracting the dried Cutleria cylindrical with solvent, preferably ethanol, filtering the extract of Cutleria cylindrical, and vacuum-concentrating and drying the filtered Cutleria cylindrical extract, and is formulated as powder, granule, tablet, capsule, suspension, emulsion, syrup, aerosol, ointment, cream, suppository or sterile injection solution, wherein the daily dosage of the Cutleria cylindrical extract is 0.001-1000 mg/kg.

Description

Pharmaceutical Composition for cancer chemoprevention comprising the extracts of Cutleria cylindrica}

The present invention is a seaweed whip ( Cutleria) cylindrica ) relates to a composition for chemical cancer prevention (cancer chemoprevention) containing the extract as an active ingredient, more specifically, the extract prepared by extracting the whip with an organic solvent of ethanol is quinone reductase which is a cancer prevention indicator enzyme Induces the activity of (Quinone reductase) and has no cytotoxicity, but does not induce the activity of single-phase detoxifying enzyme system, but shows the chemical cancer prevention effect by inducing the activity of two-phase detoxifying enzyme system. It relates to a composition of medicine for.

Even after more than 30 years of cancer research, the incidence of cancer continues to increase due to environmental pollution and poor dietary habits, causing about 10 million people worldwide each year. The World Health Organization (WHO) is one of the leading causes of death. Cancer is counted as one. Cancer is a middle-aged disease, and it is unavoidable that more than 70% of new clinical cases are diagnosed at age 60 or older and the incidence of cancer increases as the world population ages. According to the Ministry of Health and Welfare, about 100,000 cancer patients occur every year.

Common treatments for cancer include surgery, radiation, and chemotherapy. To reliably treat cancer, cancer is diagnosed and operated early, and radiation or chemotherapy is combined. However, when the diagnosis of cancer is delayed or the cancer has spread, the treatment methods are complicated and the mental and economic burden of the treatment is much greater. Therefore, chemical cancer prevention and the development of diagnostic methods for early detection of cancer are important areas of recent cancer research.

Conventional anticancer treatments can cause serious toxicity and side effects by damaging not only cancer cells but also normal cells, whereas chemical cancer prevention is achieved by artificially inhibiting, delaying or reversing the carcinogenic process using safe chemicals that are relatively nontoxic. It's a new strategy in cancer research to prevent cells from turning into cancer cells. In order to be a candidate for a chemical cancer prevention substance, the compound should be non-toxic or weak and vegetable compounds are mainly used except for some vitamin metabolites because chemicals that can be easily separated or synthesized from natural products are used for widespread use. Sur YJ, Nature Rev Cancer , 3, 768-780, 2003).

Cancer has multiple stages, such as initiation, promotion, progression and metastasis. Chemical cancer prevention aims primarily at suppressing cancer initiation and promotion. It is divided into two types according to the mechanism. That is, a blocking agent having a mechanism for inhibiting the carcinogen reacting with the intracellular target or reaching the target and a suppressing agent for suppressing the process in which the cells exposed to the carcinogen appear as neoplasia. (suppressing agent) (Surh YJ, Nature Rev Cancer , 3, 768-780, 2003). Blocking agents include: 1) diallyl sulfide, isothiocyanate, and ellagic acid, which are inhibitors of the cytochrome P-450 enzyme. And 2) phenylethyl isothiocyanate, sulfoaphane, oltipraz, and the like, which are derivatives of a two-phase detoxification enzyme. Suppressing agents include: 1) DFMO as a polyamine metabolism inhibitor; 2) a retinoid family as a cell differentiation promoter; 3) a genistein as a protein kinase C inhibitor; 4) oxidative EGCG and the like are known as DNA damage inhibitors.

Blocking agents having a mechanism for regulating the activity of the detoxifying enzyme system can be divided into two groups, monofunctional inducers and bifunctional inducers, depending on their function. Monofunctional inducers induce the activity of biphasic detoxifying enzymes such as quinone reductase and glutathione-S-transferase, while bifunctional inducers are biphasic detoxifying enzymes induced by monofunctional inducers. In addition to inducing the activity of the cytochrome P-450 family of phase 1 detoxification enzymes are also induced. In general, the increase in activity of the two-phase detoxifying enzyme system is known to be related to the preventive effect against chemical carcinogenesis by promoting the in vitro release of carcinogenic or pro-carcinogenic substances. It is known to metabolize or increase carcinogenicity. Thus, in the prevention of chemical cancer, monofunctional inducers are more effective than dual inducers (Prochaska HJ and Talalay P, Cancer). Res , 48, 4776-4782, 1988).

Gene regulation of the detoxification enzyme system by chemical cancer prevention has been reported to involve two regulators, an antioxidant response element (ARE) and a Xenobiotics-responsive element (XRE). Okey AB et al . , Toxicol Lett , 70, 1-22). Since ARE modulates the activity induction of biphasic detoxification enzymes, it can be used to test the effects of monofunctional inducers. Can be used.

The whip of the present invention ( Cutleria cylindrica ) is greenish brown, the oily body is 30-50cm in height, brown hairs on the base, long circumferentially elongated, 2-3mm thick, broadly branched in the car phase, the top is thin and the ends are changed to hair. . This hair is lost when aging. The speed decays and becomes hollow. Her spouses form a group and become irregular circular humps. This is scattered all over the pillow. It is located on a rock in a quiet area of intertidal zone, especially in tide pools in spring. It is mainly distributed in Japan, and is distributed in Daejin, Samcheok, Fupo, Kiseong, Busan, and Odongdo in Korea (Gangjewon, Korean flora and fauna book, Samhwa Publisher, 1968).

The inventors of the present invention, while searching for the activity of a monofunctional inducer in edible natural products to develop a chemical cancer preventive agent that is not toxic or weak in humans, the whip extract induces the activity of quinone reductase, a cancer prevention marker, It is not toxic and does not induce the activity of single-phase detoxifying enzyme system, but it shows chemical cancer prevention effect by inducing activity of two-phase detoxifying enzyme system, and thus the composition containing it as an active ingredient can be used as medicine for cancer prevention. The invention was completed.

It is an object of the present invention to provide a composition for a medicament containing a whip extract as an active ingredient having excellent chemical cancer prevention effect without human toxicity.

The present invention relates to a pharmaceutical composition for preventing cancer, comprising a whip extract as an active ingredient.

The whip extract of the present invention induces the activity of quinone reductase, a cancer prevention indicator enzyme, has no cytotoxicity, and does not induce the activity of the phase 1 detoxase system, but induces the activity of the phase 2 detoxase system. The composition containing it as an active ingredient is useful as a medicine for preventing cancer because it exhibits a prophylactic effect against chemical carcinogenesis by inhibiting the carcinogenicity or increase of carcinogenic substances and promoting the ex vivo release of carcinogenic or precarcinogenic substances. Can be used.

In order to achieve the above object, the pharmaceutical composition according to the present invention is characterized by containing a whip extract as an active ingredient.

The pharmaceutical composition according to one embodiment of the present invention is characterized by having a use for chemical cancer prevention.

In the pharmaceutical composition according to an embodiment of the present invention, the whip extract is preferably an ethanol extract.

In the pharmaceutical composition according to an embodiment of the present invention, the whip extract is characterized in that to enhance the activity of quinone reductase.

In the pharmaceutical composition according to an embodiment of the present invention, the whip extract is characterized by inducing activity of a biphasic detoxifying enzyme system.

Hereinafter, the present invention will be described in detail.

As used herein, the term "anticancer" is the broadest meaning encompassing all of the prevention, treatment, alleviation and alleviation of symptoms.

As used herein, the term "chemical cancer prevention" is the broadest meaning including inhibiting any one or more of the initiation stage, promotion stage, progression stage, and metastasis stage of cancer. Among them, it refers to inhibiting cancer development at the onset and promotion stage of cancer. It also includes preventing cancer through a blocking mechanism that inhibits the carcinogen from reacting with or reaching the target within the cell. It also includes preventing cancer through a suppressing mechanism that inhibits the processes in which cells exposed to carcinogens appear as neoplasia. It also includes preventing cancer by facilitating ex vivo release of carcinogenic or precarcinogenic substances. It also includes metabolizing precancerous substances to prevent cancer.

As used herein, the term "whipped horse extract" includes all of them, without particular limitation, as long as they are obtained by extracting an active ingredient from a natural whip. For example, the result obtained by putting a whip into water or an organic solvent and eluting an effective component through means, such as standing, stirring, pressurization, or heating, is mentioned. It also includes a lyophilized product obtained by lyophilizing the liquid extract thus obtained. It also includes a powder obtained by grinding such lyophilisate. In addition, any possible means for extracting the active ingredient includes all the extracted extracts, including all the processed after extraction and freeze-drying. Others include extracts obtained by conventional extraction methods such as extraction by baths or room temperature, or by conventional extraction methods described in Chinese medicine or textbooks. In addition, it includes a fraction extract obtained through the Stass Otto extraction method, various column chromatography methods, etc., which is a special extraction method for separating specific active compounds.

The present invention provides a whip extract for chemical cancer prevention.

The whip may be used without limitation, such as harvested, cultured or commercially available, the solvent for extraction is ethanol. The present inventors washed the whip with water to remove foreign substances and salt, and then dried and extracted, and the filtrate was concentrated under reduced pressure and dried to obtain a whip extract.

The present invention also provides a chemical cancer prevention pharmaceutical composition containing the lash extract as an active ingredient.

The pharmaceutical compositions according to the invention may further comprise suitable carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions.

The pharmaceutical dosage forms of the compositions of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active compounds as well as in a suitable collection. The salt is not particularly limited as long as it is pharmaceutically acceptable, and for example, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrofluoric acid, hydrobromic acid, formic acid acetic acid, tartaric acid, lactic acid, citric acid, fumaric acid, maleic acid, succinic acid, methanesulfonic acid , Benzene sulfonic acid, toluene sulfonic acid, naphthalene sulfonic acid and the like can be used.

The pharmaceutical compositions according to the present invention may be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, oral formulations, ointments, creams, external preparations, suppositories, and sterile injectable solutions. It may be used in formulated in any form suitable for pharmaceutical formulations.

In the composition according to the present invention, the preferred dosage of the whip extract depends on the subject's age, sex, weight, symptoms, degree of disease, drug form, route of administration, and duration, and may be appropriately selected by those skilled in the art. . However, for the desired effect, the whip extract of the present invention is preferably administered at 0.001 to 1000 mg / kg per day. Administration may be administered once a day or may be divided several times. In addition, the dosage may be increased or decreased depending on age, sex, weight, degree of disease, route of administration, and the like. Therefore, the above dosage does not limit the scope of the present invention in any aspect.

The composition according to the present invention can be administered to mammals such as rats, mice, livestock, humans by various routes, such as parenteral, oral, and all modes of administration can be expected, for example, oral, rectal Or by intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.

On the other hand, the composition according to the present invention, there is no serious toxicity and side effects can be used with confidence even for long-term use for the purpose of prevention.

The composition according to the present invention may contain 0.001 to 99.9% by weight of the whip extract as the active ingredient in the total weight of the composition. This is because the effect can be expected to be 0.001% by weight or more, it is difficult to exceed 99.9% by weight due to the presence of impurities.

On the other hand, in the case of formulating a whip extract of the present invention into tablets, capsules, chewing tablets, small bags, granules, powders, liquid solutions, suspensions, dispersions, emulsions, syrups and the like for the purpose of oral administration, Arabia Rubber, corn starch, binders such as microcrystalline cellulose or gelatin, excipients such as dicalcium phosphate or lactose, disintegrants such as alginic acid, corn starch or potato starch, lubricants such as magnesium stearate, sucrose or saccharin Sweetening agents and flavoring agents such as peppermint, methyl salicylate or fruit flavors may be included, and in the case of the dosage unit form of capsules, liquid carriers such as polyethylene glycol or fatty oils may be included in addition to the above components.

The present invention also provides a health functional food composition comprising the whip extract and a food supplement acceptable food supplement. The food composition according to the present invention may be, for example, a health functional food product including chewing gum, caramel products, candy, ice cream, confectionery, various food products such as soft drinks, mineral water, alcoholic beverages, vitamins and minerals, and the like. Can be.

At this time, the amount of the whip extract in the food can be added to 0.001 to 99.9% by weight of the total food weight, in the beverage in the ratio of 0.001 to 0.1 g, more preferably 0.05 to 0.1 g based on 100 ml Can be.

The beverage containing the whip extract of the present invention is an essential ingredient in the ratio indicated, and there are no special limitations on the other ingredients except the whip extract, and various flavors or natural carbohydrates, such as ordinary drinks, may be added as additional ingredients. It may contain.

In addition to the above, the functional food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), synthetic flavors such as synthetic and natural flavors, colorants and enhancers (such as cheese and chocolate), pectic acid and salts thereof, alginic acid And salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the functional food compositions of the present invention may contain fruit flesh for the production of natural fruit juices and fruit juice beverages and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected from the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.

The present inventors conducted an experiment in rat liver cancer cell line (Hepa1c1c7) in order to determine the effect of quinone reductase activity, a cancer prevention indicator enzyme of the whip extract. The whip extract of the present invention was confirmed to increase the quinone reductase activity by two-fold and 2.7-fold, respectively, at a concentration of 50 and 100 μg / ml.

In addition, the whip end of the present invention extracts the 50% inhibitory concentration of IC ₅₀ of cell growth is calculated as 705 μg / ml showed a cytotoxic or weak.

In addition, experiments were conducted on human liver cancer cell lines (HepG2) to determine the effect on the phase 1 and 2 detoxification enzyme activity of the whip extract of the present invention. The whip extract of the present invention did not affect the XRE activity inducing both phase 1 and phase 2 detoxifying enzyme activity at concentrations of 1, 10 and 100 μg / ml, and the ARE activity inducing the phase 2 detoxifying enzyme activity. It was found to affect concentration-dependently. This demonstrates the effective chemical cancer prevention effect of the whip extract of the present invention to selectively increase the activity of the biphasic detoxifying enzyme system.

Hereinafter, the present invention will be described in detail by the following Examples and Experimental Examples.

However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following Examples and Experimental Examples.

< Example  1> Whip  Preparation of Extract

Wash the whip collected in Geumjin, Gangneung-si, Gangwon-do with water, remove foreign substances and salt, dry it, grind it to a suitable size, add 20 g of whip and 500 ml of ethanol water solution to the extraction container, and cool it under reflux. To obtain an extract. The extraction process was repeated four times, after which the solvent was concentrated under reduced pressure and dried to obtain 880 mg of ethanol extract.

< Experimental Example  1> Whip  Quinones in Extract Reductase  Activity Induction Effect Measurement

The present inventors conducted an experiment in the rat liver cancer cell line (Hepa1c1c7) in order to determine the effect of quinone reductase activity, a cancer prevention indicator enzyme of the whip extract of the present invention. First, mix the a-MEM (minimum essential medium) / 10% FBS (fetal bovine serum) solution with the liver cancer cell culture medium to determine the number of cells 1X10 ⁵ After adjusted to cells / ml treated in 100 μl in 96well plate and incubated under the conditions of 5% CO _2/37 ℃ for 24 hours. After the cells are stabilized the <Example 1> an extract of the whip end obtained in 25, 50, and cultured under the conditions of 5% CO _2/37 ℃ during treatment with 100 μg / ml concentration in 24 hours. After incubation, the cells were washed with PBS (phosphate buffered saline) solution, and the cell membrane was lysed with 80 μl of a solution containing 0.08% digitonin and 2 mM EDTA to obtain a protein solution. 50 μl of protein solution and reaction solution A (49 ml of 25 mM Tris buffer, 34 mg of BSA, 0.34 ml of 1.5% Tween-20 solution, 0.34 ml of coenzyme solution, 100 units of glucose-6-postate dehydro) 200 ul of genease, 15 mg MTT, 50 μl of 50 mM menadione) was mixed and the absorbance increase was measured at 610 nm using a microplate reader, and the amount of protein was measured at 595 nm using a Bradford solution. Obtained. The crude enzyme solution in the reaction solution A was composed of 150 mM glucose-6-phosphate, 4.5 mM NADP, 0.75 mM FAD, and the MTT was 3- (4,5-dimethylthiazo-2. -yl) -2,5-diphenyltetrazolium bromide. The quinone reductase activity was calculated by the following equation.

(Equation 1)

Quinone reductase activity = A / B

A: nmol MTT / min (increase in absorbance at 610 nm of intracellular quinone reductase treated with whip extract)

B: mg protein (amount of protein in cells treated with whip extract)

As a result, as shown in Figure 1, the whip extract of the present invention was confirmed to increase the quinone reductase activity by two-fold, 2.7-fold, respectively, compared to the untreated control at the concentration of 50, 100 μg / ml.

< Experimental Example  2> Whip  Cytotoxicity of Extracts

The present inventors conducted an experiment in the rat liver cancer cell line (Hepa1c1c7) to measure the cytotoxicity of the whip extract of the present invention. First, mix the a-MEM / 10% FBS solution with the hepatocellular cell culture medium to obtain ⁵ × 10 ⁴ cells. After adjusted to cells / ml treated in 100 μl in 96well plate and incubated under the conditions of 5% CO _2/37 ℃ for 24 hours. After the cells are stabilized the <Example 1> an extract of the whip end obtained in a two-fold concentration gradient treated with five concentrations between 12.5-200 μg / ml and 5% CO ₂ for 24 hours / the conditions of 37 ℃ Incubated at. After incubation, 10 μl of Cell Counting Kit (CCK-8, Dojindo Laboratories) was treated for 3 hours, and the absorbance was measured at 450 nm with a microplate reader. The cell proliferation rate represents the absorbance of the cells treated with the extract of the whip obtained in <Example 1> in% when the absorbance of the untreated cells was 100%.

As a result, as shown in Figure 2, the whip extract obtained in Example 1 was calculated as IC ₅₀ of 50% inhibitory concentration of cell proliferation was 705 μg / ml, it was shown that there is no cytotoxic or weak.

< Experimental Example  3> Whip  Of extract XRE The effect on

The present inventors report the reporter gene assay of XRE in human liver cancer cell line (HepG2) in order to measure the effect on the XRE that induces the activity of the phase 1 and 2 detoxifying enzyme system of the whip extract of the present invention. ) Was performed. First, the DMEM (Dulbeco's minimum essential medium) / 10% FBS solution was mixed with the liver cancer cell culture medium to change the number of cells 1X10 ⁵ After adjusted to cells / ml and cultured under the conditions of 5% CO _2/37 ℃ W and treated in 500 μl in the 48well plate. After the cells were stabilized, a vector containing a promoter containing XRE and a chloramphenicol acetyl transferase (CAT) protein expression gene was transformed using Fugene6 (Roche Biochemicals). After the cells were cultured in the stabilized <Example 1> under the conditions of the whip extract treated with the 1, 10, 100 μg / ml concentration of a horse and 5% CO ₂ for 24 hours / 37 ℃ obtained in. After the incubation, CAT-ELISA Kit (Roche Biochemicals) was used to measure the expression level of CAT protein. The expression rate of CAT protein was expressed as the ratio of expression rates in cells treated with whip extract when the expression rate of CAT protein in untreated cells was 1. The experiment was carried out using 3-MC (3-methylcolanthrene, Sigma), a carcinogen known to increase the activity of XRE as a positive control.

As shown in Figure 3, the whip extract of <Example 1> was confirmed that there is no concentration-dependent effect on the XRE to induce the activities of the phase 1 and 2 detoxification enzyme system.

< Experimental Example  4> Whip  Of extract ARE The effect on

The present inventors performed a reporter assay of ARE in human liver cancer cell line (HepG2) in order to measure the effect on the ARE inducing the activity of the two-phase detoxification enzyme system of the whip extract of the present invention. First, mix the DMEM / 10% FBS solution with the liver cancer cell culture medium and change the number of cells to 1 × 10 ^5. After adjusted to cells / ml and treated in 500 μl in 48well plate and incubated under the conditions of 5% CO _2/37 ℃. After the cells were stabilized, the promoter containing the ARE and the vector into which the CAT protein expression gene was inserted were transformed using Fugene6 (Roche Biochemicals). After the cells were cultured in the stabilized <Example 1> under the conditions of the whip extract treated with the 1, 10, 100 μg / ml concentration of a horse and 5% CO ₂ for 24 hours / 37 ℃ obtained in. After the incubation, CAT-ELISA Kit (Roche Biochemicals) was used to measure the expression level of CAT protein. The expression rate of the CAT protein was expressed as the ratio of the expression rate of the cells treated with the whip extract when the expression rate of the CAT protein in the untreated cells was 1.

As shown in Figure 4, it was confirmed that as the treatment concentration of the whip extract of <Example 1> increased the activity of the ARE concentration-dependently.

From Experimental Example 3 and Experimental Example 4, the whip extract of the present invention was found to have an effective chemical cancer prevention effect to selectively increase the activity of the biphasic detoxifying enzyme system.

Hereinafter, the preparation examples of the composition according to an embodiment of the present invention will be described, but the present invention is not intended to be limited thereto but merely to be described in detail.

Formulation example  1. Preparation of Tablets

Whip extract of Example 1. … … … .100 mg

Corn Starch ... … … … … … … … … … … … … … … .68 mg

Lactose ... … … … … … … … … … … … … … … … … 90 mg

Microcrystalline cellulose… … … … … … … … … … … ..40 mg

Magnesium stearate … … … … … … … … … … 2 mg

According to the conventional method of preparing tablets, the above ingredients were added to the indicated contents, mixed uniformly, stirred and granulated. After drying, using a tableting machine, a desired tablet containing 100 mg of a whip extract as an active ingredient was prepared.

Formulation example  2. Preparation of capsule

Whip extract of Example 1. … … … … 100 mg

Corn Starch ... … … … … … … … … … … … … … … … ..68 mg

Lactose ... … … … … … … … … … … … … … … … … … .90 mg

Microcrystalline cellulose… … … … … … … … … … … … … 40 mg

Magnesium Stearate … … … … … … … … … … … 2 mg

According to the conventional method for preparing the capsules, the above-mentioned ingredients were added and mixed uniformly, and then the desired capsules were prepared by filling into gelatin capsules of an appropriate size such that 100 mg of whiplash extract was contained per capsule.

Formulation example  3. Chewing Definition  Produce

Whip extract of Example 1. … … … … … 100 mg

Granulated sugar syrup … … … … … … … … … … … … … … … … .240 mg

Spices… … … … … … … … … … … … … … … … … … … … … 2 mg

Corn Starch ... … … … … … … … … … … … … … … … … 60 mg

Mannitol… … … … … … … … … … … … … … … … … … … .100 mg

Magnesium stearate … … … … … … … … … … … ..20 mg

Purified water… … … … … … … … … … … … … … … … … … … ..Appropriate

According to a conventional method of preparing chewing tablets, the above ingredients are mixed in an appropriate amount of water, dissolved while heating, cooled and placed in a molding machine so that 100 mg of whiplash extract per one is included. Prepared.

Formulation example  4. Manufacture of Candy

Whip extract of Example 1. … … … … 100 mg

Granulated sugar syrup … … … … … … … … … … … … … … … .640 mg

Spices… … … … … … … … … … … … … … … … … … … … 2 mg

corn syrup… … … … … … … … … … … … … … … … … … … … 230 mg

50% tartaric acid… … … … … … … … … … … … … … … .20 mg

Purified water… … … … … … … … … … … … … … … … … … … Appropriate amount

The granulated sugar syrup was heated to 110 ° C. while completely dissolving in a small amount of water, and then the remaining water and starch syrup was dissolved, and the temperature was raised to 145 ° C. The fire was turned off, the fragrance and tartaric acid were added, mixed, cooled to 75-80 ° C., and molded with a forming roller to prepare a candy containing whip extract.

Formulation example  5. Manufacture of drinks

Whip extract of Example 1. … … … … 100 mg

Concentrated Juicer… .… … … … … … … … … … … … … … … … .2 g

Sucrose… … … … … … … … … … … … … … … … … … 12 g

Sodium citrate… … … … … … … … … … … … … … .100 mg

Spices… … … … … … … … … … … … … … … … … … … … .70 mg

water… … … … … … … … … … … … … … … … … … … … Appropriate amount

According to the conventional method for preparing a beverage, the above ingredients are mixed in an appropriate amount of water in a given content, heated to dissolve, cooled, and filled into a container to obtain 100 mg of whiplash extract per bottle of 200 ml of beverage. A beverage containing was prepared.

1 is a whip of the present invention ( Cutleria) cylindrica ) extract shows the effect of quinone reductase activity inducing,

Figure 2 is a diagram showing the cytotoxicity evaluation of the whip extract of the present invention,

Figure 3 is a diagram showing the effect on the Xenobiotics-responsive element (XRE) of the whip extract of the present invention (3-methylcolanthrene treatment control),

Figure 4 is a view showing the effect on the antioxidant response element (ARE) of the whip extract of the present invention.

Claims (5)

Cancer preventive pharmaceutical composition containing a whip extract as an active ingredient. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition has a use for chemical cancer prevention. The pharmaceutical composition according to claim 1 or 2, wherein the whip extract is an ethanol extract. The pharmaceutical composition according to claim 1 or 2, wherein the whip extract enhances the activity of quinone reductase. The pharmaceutical composition according to claim 1 or 2, wherein the whip extract induces activity of a biphasic detoxifying enzyme system.

Images